Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

Inclusion Criteria: * Clinically confirmed diagnosis of recurrent respiratory papillomatosis. * Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required. * Human papilloma virus (HPV)6+ RRP in larynx * ECOG (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I). * The following laboratory values obtained ≤ 28 days prior to apheresis. * Absolute neutrophil count (ANC) ≥1.0 x 109 /L * Platelet count (PLT) ≥ 75 x 109 /L * Hemoglobin ≥ 8.5 g/dL * Lymphocytes ≥ 0.3 x 109 /L * Total bilirubin ≤ 2 x upper limit of normal (ULN), unless patient has a documented history of Gilbert's disease, then Direct bilirubin ≤1.0 mg/dL. * Aspartate transaminase (AST) ≤ 3 x ULN * Creatinine ≤ 2.0 mg/dL * Monocytes ≥ 0.25 x 109 /L * Able to provide informed written consent. * Willingness to return to Mayo Clinic Arizona for follow-up appointments * Willingness to provide blood samples for immune assessment and other tests * Willingness to provide papilloma tissues that will be surgically removed * Agree that during the trial, male participants will not father a child and female participants cannot be or become pregnant if they are of child-bearing potential. *…